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Summary The pathological and biological features of a consecutive series of impalpable invasive breast
carcinoma, detected by mammography in the prevalent round of the breast screening programme, have been
compared with a clinically presenting group of carcinomas in age-matched patients. There was a significantly
higher prevalence of tubular carcinomas and well-differentiated infiltrating ductal carcinomas in the mammog-
raphically detected group, and a lower prevalence of poorly differentiated infiltrating ductal carcinomas.
Lymph node metastasis was found in 6.5% of the impalpable group compared with 53% of the clinical group.
The prevalence of oestrogen receptor was much higher in the impalpable group (96%) than in the control
group (67%), although there were no significant differences for progesterone receptor. The prevalence of pS2
was also much higher in the impalpable group, as was cathepsin D. This finding is surpn'sing in view of the
reported relationship between cathepsin D and poorer survival. p53 and c-erb-2 proteins were detectable in
fewer impalpable carcinomas. The mean MIBI (Ki-67) index was lower in the impalpable group (11.6) than in
the clinical group (15.25). Within the mammographically detected group there was a significant difference in
the MIBI index between tubular carcinomas and the different grades of infiltrating ductal carcinomas, with a
wide range in each category but no association with size. The impalpable carcinomas detected by mammo-
graphy differ from clinically presenting carcinomas in many ways. raising the question of whether a proportion
or all would progress (dedifferentiate) with time.
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Screening for breast cancer by mammography is increasing in
frequency throughout the world. This is because findings
from several studies, have shown that a reduction in mor-
tality can be achieved (Verbeek et al., 1984; Shapiro et al.,
1985; Tabar et al., 1985), although the reduction has been
less in some studies (Chamberlain et al., 1988; Roberts et al.,
1990). The key factors are considered to be the smaller size
of screen-detected cancers and the lower frequency of nodal
metastasis. However, there may be other factors since
detailed pathological studies have shown that the carcinomas
detected in prevalent screens are of a more favourable type
and grade (Anderson et al., 1986, 1991).
One of the major problems in studying the biological
nature of the small carcinomas detected by mammography
has been the techniques and reagents which could be used to
analyse formalin-fixed, paraffin-embedded tissue. The int-
roduction of a wider range of antibodies applicable to fixed
tissue and antigen retrieval methods, can overcome this. This
study was concerned with examining carcinomas detected by
mammography for various markers associated with different
patterns of behaviour, e.g. oestrogen receptor, the presence
of which is linked with better differentiation (Bruun Ras-
mussen et al., 1981), and c-erbB-2 protein and p53, which are
associated with more aggressive features (Walker et al., 1989,
1991). The carcinomas were compared with a group of
clinically presenting invasive carcinomas in age-matched
patients with respect to oestrogen and progesterone receptor,
the oestrogen-regulated protein pS2, cathepsin D, c-erbB-2,
p53, proliferation as determined by Ki-67 and pathological
features.
Material and methods
Patients
Tissue from 107 invasive breast carcinomas detected by the
Leicestershire Breast Screening Service during the period
1990-92 was exaamined. The carcinomas were detected by the
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prevalent screen and formed a consecutive series of car-
cinomas that were not clinically palpable. Fifty-eight had
been excised after stereotactic localisation, 20 had been
excised under ultrasound guidance and 29 had been excised
using the mammographic findings as a guide. All patients
had either axillary node sampling of 3-4 nodes (22 cases) or
level 1 axillary dissection of 9-15 nodes (85 cases).
The control group comprised 70 carcinomas from patients
aged between 50 and 67 years who had undergone surgery
between 1985 and 1990 and for whom all marker data were
available. None of these patients had been screened.
Tissues
All tissues were fixed in 4% formaldehyde in saline for 18 h.
After slicing, selected blocks were processed through graded
alcohols and xylene to paraffin wax. Following review of
haematoxylin and eosin-stained sections a representative
block was chosen for further study.
Histology
The carcinomas were reported according to the Royal Col-
lege of Pathologists working party guidelines (1990).
Infiltrating ductal carcinomas were graded using the modified
Bloom and Richardson system (Elston and Ellis, 1991). All
histology was undertaken by R.A.W.
Antibodies
The following were employed: anti-oestrogen receptor mouse
monoclonal antibody (1D5) (Dako), which reacts with the
N-terminal domain of the receptor; anti-progesterone recep-
tor mouse monoclonal antibody (NCL-PgR) from Novocas-
tra; MIBI mouse monoclonal antibody against the Ki-67
antigen (Binding site) (Cattoretti et al., 1992); mouse mono-
clonal antibody against cathepsin D (NCL CDm) from
Novocastra; anti-pS2 mouse monoclonal antibody (Histo
CIS pS2, CIS UK); polyclonal rabbit anti-p53 antiserum
(CM1) (a gift from D Lane); and mouse monoclonal anti
c-erbB-2 antibody (NCL CB11) from Novocastra. All
secondary reagents were from Dako.Netm oiFkaiple ibreast cw
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Immunohistochemistrv
ER, PgR and MIBI Formalin-fixed, paraffin-embedded sec-
tions were mounted on slides coated with silane (3-
aminopropyltriethoxysilane, BDH) and immersed in 10 mm
citric acid buffer, pH 6.0. For ER and MIBI, the sections
were exposed to three cycles, each of 5 min, of microwave
irradiation using an 800 W microwave on maximum power.
For PgR two cycles were used. The antibodies were applied
as follows: ID5, 1:100 dilution in Tris-buffered saline pH 7.4;
NCL PgR, 1:70 dilution; MIBI, 1:50 dilution; all for 18 h at
4°C. Biotinylated rabbit anti-mouse immunoglobulin
antiserum followed by streptavidin-peroxidase was the
detection system, and peroxidase was localised using
diaminobenzidine-hydrogen peroxide.
pS2, Cathepsin D, c-erbB-2, p53 For the detection of
cathepsin D, sections were treated with 0.05% protease type
14 for 10 min at 37C. No pretreatment was used for the
detection of the other antigens. The antibodies were applied
as follows: pS2, neat; NCL-CDm, 1:100 dilution; NCL-
CBl1, 1:80; CM1, 1:80; for 18h at 4°C. The three mono-
clonal antibodies were detected using biotinylated rabbit anti-
mouse immunoglobulin antiserum, and CM 1 using
biotinylated swine anti-rabbit immunoglobulin antiserum,
followed by streptavidin-peroxidase complex as above and
diaminobenzidine-hydrogen peroxide detection.
Controls in all instances were the omission of the primary
antibody and the inclusion of a known positive with each
staining batch.
Evaluation
An H-score was calculated for the ER and PgR staining of
each tumour (McClelland et al., 1991). The percentages of
cells deemed weakly positive (i), moderately positive (ii) and
strongly positive (iii) were determined by counting 500-1,000
nuclei per section. The formula (i x 1) + (ii x 2) + (iii x 3)
was applied. An H score greater than 50 was considered
positive, following UK Steroid Receptor Quality Assessment
guidelines. The Ki-67 (MIBI) index was assessed by counting
a minimum of 500 nuclei and calculating the percentage of
stained nuclei. The percentage of cells positive for pS2 was
determined. For cathepsin D the intensity of staining and
percentage of invasive tumour cells staining were assessed; a
score of 1-3 was given for weak to strong intensity and the
percentages of cells staining were grouped as 10-25, 25-50,
50-75 and greater than 75% with a score of 1-4. The two
scores were added to give a maximum of 7. For p53 the
percentage of stained nuclei was determined with a minimum
of 500 cells being ecounted, with more than 20% of cells
having moderate or strong staining being considered positive.
Membrane staining of the majority of tumour cells for c-
erbB-2 was considered positive.
Statistics
Comparison of different groups was by j or Fisher exact
probability (two-tail) test. Comparison of two means was
performed by the Student t-test. Comparison of several
means was performed by one-way analysis of variance.
Results
Pathologicalfeatures
The findings and comparison with the control group are
shown in Table I. Thirty-nine carcinomas were 10 mm or less
in size, 56 were 1- 15mm, 10 were 16-20mm and two
carcinomas were greater than 20 mm. In the control group
there was one carcinoma less than 10mm, two of I1I -15 mm,
ten of 16-20 mm and the remainder were greater than
20mm.
The major differences were the higher frequency of tubular
carcinomas in the mammographic group (27%) compared
with the control (1.5%) (yj 11.43, P<0.001); the higher
frequency of well-differentiated infiltrating ductal carcinomas
(36% compared with 15.0%) and the lower incidence of
poorly differentiated tumours (9.0% compared with 37.0%)
(j 17.6, P<0.001); the lower frequency of nodal metastasis
(6.5% compared with 55.0%) (X2 = 53.1, P<0.001).
The relationship between the size of the mammographi-
cally detected carcinomas and differentiation is shown in
Table II. There were more moderately differentiated infil-
trating ductal carcinomas which were greater than 10mm,
but this was not significant.
Oestrogen andprogesterone receptors
One hundred and three of the 107 mammographically
detected carcinomas (96.0%) were ER positive. The H-scores
ranged from 67.5 to 266, with seven having scores between
50 and 100, 64 between 100 and 200 and 32 greater than 200.
In the control group 47 (67%) were ER positive (Table 111).
The H-scores in this group ranged from 52 to 258, with 13
being between 50 and 100, 24 between 100 and 200 and nine
greater than 200. There was a significant difference in the
number of cases which were ER positive between the two
groups (X: 31.7, P<0.001).
In the mammographically detected group the mean H-
score for the tubular carcinomas was 179, for well-
differentiated infiltrating ductal carcinomas 160 and for
moderately differentiated infiltrating ductal carcinomas 168.
Table I Histological characteristics of the mammographically
detected and control carcinomas
Mamnographic Control
Type
Infiltrating ductal 69/107 (64.5%) 60/70 (85.5%)
Infiltrating lobular 8/107 (7.5%) 6/70 (8.5%)
Tubular 29/107 (27.0%) 1 70 (1.5%)
Tubulolobular 1/107 (0.9%) 0
Medulary 0 1/70 (1.5%)
Papillary 0 2'70 (3.0%)
Grade
I 25X69 (36.0%) 9,60 (15.0%)
II 38169 (55.0%) 29/60 (48.0%)
III 6/69 (9.0%) 22160 (37.0%)
Node-status
Positive 7/10 (6.5%) 36/64 (55.0%)
Negative 100/107 (93.5%) 28/64 (45.0%)
Table II Relationship between size of mammographically detected
tumours, tubular carcinoma and the grade of infiltrating ductal
carcinomas
Size (mm) Tubular Grade I Grade II Grade III
10 14 12 10 2
11 -15 14 12 21 4
16-20 0 1 7 0
>20 1 0 0 0
Table m Comparison ofmammographically detected and clinically
presenting carcinomas for different markers
Mammographic Control
carcinomas carcinomas
Oestrogen receptor 103/107 (96%) 47/70 (67.0%) P<0.001
Progesterone 63/107 (59%) 34/70 (48.5%) NS
receptor
pS2-cytoplasrmic 104/107 (80.0%) 49'70 (70.0%) P<0.001
and membrane
pS2-cytoplasmic 85 107 (80.0%) 40 70 (57.0%) P<0.001
only
Cathepsin D 96 107 (90.0%) 34 70 (48.5%) P<0.001
p53 9/107 (8.4%) 26/70 (37.0%) P<0.001
c-erbB-2 4/107 (3.7%) 12/70 (17.0%) P<0.05
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There was a significnt difference between these and the
mnean H-score for the poorly differentiated of 118 (P, 0.05,
one-way anlysis ofvariance). All ofthe four mammographi-
call de d carcinomas that were ER negative were
infiltaing ductal, one being well differentiated, one
moderately and two poorly differentiated. There was no rela-
tionship between ER status, H-score and tumour size.
Fifty nine per cent of the deece
carcmomas were positive for PgR, while 48.5% ofthe control
group were positive. The difference between the two groups
was not significant. Sixty per cent of the ER-positive mam-
moaphilly det carcnomas wve PgR positive, and
only one tumour was ER negative, PgR positive. The tubular
and welfferentiated infiltrating ductal arcinomas were
more likely to be PgR positive (79% and 72% respectively).
than the moderate (49%) or poorly differentiated (2/6) infil-
trating ductal carcnomas (2 12.68, P<0.001).
pS2
Staining was either within the cytoplasm ofcells or at the cell
membrane, which was pdomintly himinal. Carcinomas
were considered positive if more than 10% of cells stained.
Membrane ining only was observed in 19 mammographi-
cal deted carcnomas, cytoplasxnc staiing only in 44
and a combined pattern in 41. Only three carcinomas were
classid as negative if both cytoplasic and membrane
ining was considered, giving a positive rate of 97.0a/.. If
only cytoplasmic reactivity was taken into aaount, 80%
were positive. There was a sigficant dife from the
control group (Table HI), which was greater if both staining
patterns were consided (X2 26.65, P<0.001).
Staining relating only to membrans was seen pre-
dominantly in tubular and well-differniated infiltatng duc-
tal carcinomas. Eleven of the 29 tubular caranomas had this
pattern of staining, and a further 17 tubular carciomas had
both membrane and cytoplasmic reactivity, with only one
exhibiting cytoplasmic staining only.
Most tumours were both ER and pS2 positive. Ofthe four
ER-negative tumours all were pS2 positiv, and of the three
pS2-negative tumours two wer ER positive.
Cathepsi D
Only sang ofcarinoma cells was consdered. The staining
indces were grouped as 2-3, weak; 4-5, moderate; 6-7
strong. Reactivity was seen in 96 madete
carcinomas (90%), with 51 (47.6%) having strong ing,
26 (24%) moderate and 19 (18%) weak eactivity. There was
a signifat difference in the frequency ofcathepsin D in the
mammographically detected group compared with the con-
trol (Table EII) (e = 39, P<0.001). Also, the mam-
mogrphically deted carcinomas were more likely to stain
strongly (X2 41.41, P<0.001).
Cathepsin D staining was associated with the size of the
tumour, with positive tumours more likely to be < 15 mm (X2
7.1, P<0.01). There was decreasing positivity with increas-
ing grade, but this was not signiant. There was no correla-
tion between ER and cathepsin D.
trol group (Fisher exact two-tail test, P<0.05). All were
moderately differentiated infiltrating ductal carcinomas with
Si ranng from 8 to 17 mm, and were ER positive.
Prolferation
The MIBI index ranged from 1.2 to 59.9 in the mam-
mographically detected group. The overall mean index (11.6)
was sgificantly lower than that for the control group
(t= 2.583, P<0.05). The range for this group was 1.0-50.0
with a mean of 15.25.
The mean values for the mammographically detected
group increased with histological grade. The mean value for
the tubular carcinomas was 7.48 (range 1.8-15.4), for well-
differentiated infiltrating ductal carcinomas 9.11 (range
3.5-20.7), for moderately differentiated infiltrating ductal
carcinomas 14.75 (range 1.2-59.9), and for poorly
differentiated infiltrating ductal carcinomas 26.4 (range
6.7-45.1). The increase was significant (one-way analysis of
variance, P<0.001). There were no differences in the MIBI
index with increasng sie, the key factor within any size
range being tumour grade.
There was no relationship between ER H-score and MIBI
index for the mammographially detected group, using the
mean score of 11.6 as the cut-offpoint. Thirty eight per cent
(13/34) ofthe carcinomas with H-scores greater than 200 had
a MIBI index greater than the mean and 31% (22/70) of
carcinomas with H-scores between 50 and 200 had a MIBI
index greater than the mean (Table IV). T'he majority of
carcinomas with high score and higher proliferation rates
were moderately differentiated.
DiMCN'
The aim of mammographic screening is to detect breast
carcinomas at an earlier stage of their clnical course when
they are of a smaller size and are es likely to have metas-
tasised. Several studies have shown that carcinomas d d
by screeni programes have pathological and biological
characteristics which are suggestive of a lower malignant
potential (Anderson et al., 1986, 1991; Cowan et al., 1991;
Klemi et al., 1992). The present study has considered a large
number of factors and has confirmed that carcinomas which
are detected by mammography differ biologically from car-
cinomas which present clinically.
The carcinomas studied formed a conscutive series of
invasive implpable tumours. Eighty-nine per cent were
15mm or less in size, and only 6.5% showed evidence of
tastasis. This latter finding is similar to the finding ofElls
et al. (1993) for palpable carcinomas, but lower than that
ofAndeson et al. (1986), who reported tastasis in 22% of
cases. The finding of a high proportion of tubular car-
cinomas (27%) and wel-derentiated arcinomas (36% of
infiltrating ductal carcinomas) has been reported by others.
Anderson et al. (1986) found 12% tubular carcinomas and
22.5% variant tubular carcinomas. Cowan et al. (1991)
lasified 46% of all invasive carcinomas as well
p53
Nine of the my caranomas had
evidence of p53 sining (8.4%) compared with 38.8% in the
control group, which was si ntly different (X2 22.78,
P<0.001). All of the positive tumours were moderately (6)
or poorly (3) differentiated infiltrating ductal carcinomas.
There was no difference in relation to size, using 15 mm as
the cut-off point, and only one p53-positive tumour was ER
negative.
c-erbB-2
Four of the mmmdetel carcinomas (3.7%)
Were positive, compared with 12 (17.0%) of the clinical con-
Tale IV Comparison of ER H-score and proliferation index
(MIBI, cut-off pont = mean value) in relation to type and grade of
_b detected auiloma
H-score 200 and
H-score 50-199 greater
,< 11.6% > l11.6% <- 11.6% > I11.6%
Infirating ductal
Grade I
Grade H
Grade In
Tubular
Infiltrating lobular
14
12
1
3
12
2
6
3
0
10
16 3 12 0
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differentiated, and Klemi et al. (1992) 38%. Ellis et al. (1993)
found 52% of impalpable carcinomas to be tubular or
tubular muxed. Their percentage of tubular and well-
differentiated tubular mixed and infiltrating ductal (61%) is
very similar to that 63% found in this study. All of these
findings differ from those of McKinney et al. (1992), who
reported only 2.6% (2/77) tubular carcinomas and 14% well-
differentiated tumours in a series of impalpable invasive car-
cinomas.
The rate of ER positivity in this group of impalpable
carcinomas is very high in comparison with the control
group. The ability to detect ER in fixed, embedded tissue has
extended the range of carcinomas that can be studied. Stal et
al. (1992) studied screen-detected carcinomas but employed a
biochemical assay which requires fresh tissue and would not
be applicable to impalpable lesions excised under stereotactic
control. Their rate was 78%. Soomro et al. (1992) used
immunohistochemistry to assess screen-detected carcinomas
for ER and found 78% to be positive, but their series
included palpable and impalpable carcinomas. Of interest in
the present study was the finding of a group of carcinomas
with high H-scores for ER and high MIBI (proliferation)
indices.
The oestrogen-regulated protein pS2 has a good correla-
tion with ER, both in immunoassays (Foekens et al., 1990)
and in immunohistochemical studies (Henry et al., 1991;
Thor et al., 1992). It is therefore not surprising that there is a
high level of detection in the mammographic group of car-
cinomas. What is more surpnrsing is the greater level of
detection of cathepsin D in the mammographically detected
group compared with the clinical controls. This was also
found by Cowan et al. (1991), but not to the same degree of
significance. The higher incidence of cathepsin D staining in
these early breast carcinomas seems paradoxical in the light
of previous studies which have related cathepsin D to metas-
tasis and shortened disease-free interval (Spyratos et al.,
1989; Tandon et al., 1990; Pujol et al., 1993). However,
Henry et al. (1990) found cathepsin D, as determined
immunohistochemistry, to be associated with a better prog-
nosis. The critical factor may well be the cathepsin D in
macrophages, which will be measured in immunoassays of
tumour homogenates, but can be assessed separately using
immunochemistry (Walker et al., 1994).
The finding of a lower incidence of p53 and c-erbB-2 in the
mammographically detected group compared than in the
control group is not surprsing since they are associated with
poorer differentiation and lack of oestrogen receptor (Walker
et al., 1989, 1991; Allred et al., 1992; Poller et al., 1992;
Barnes et al., 1993).
The Ki-67 antigen is expressed by cells in the cell cycle
(Gerdes et al., 1984). Immunodetection can provide a useful
guide to the proliferative status of a carcinoma. The overall
mean index of the mammographically detected carcinomas
was lower than that of the control group, which is similar to
the findings of Klemi et al. (1992) for S-phase fraction.
Although there was a relationship between MIBI (Ki-67)
index and differentiation, a range of values was found for
each of the differentiation categories, with no relationship to
size.
The carcinomas detected by mammography are clearly
different from the clinically presenting group in many ways.
The question arises as to what happens to this impalpable
group with time. Linnell et al. (1980) suggested that tubular
carcinomas may progress to less differentiated carcinomas if
left untreated. The tubular mixed carcinomas described by
Ellis et al. (1992) may lend some support to this contention.
Taber et al. (1992) proposed that dedifferentiation occurs
with increasing size, but the evidence for this is circumstan-
tial. In the present study there were carcinomas 10 mm and
less which were moderately and poorly differentiated with no
evidence of tubular structures, and no features to suggest a
possible onrgin from a tubular carcinoma. It is therefore more
likely that breast carcinomas have several different lines of
development and progression, with a proportion of impal-
pable carcinomas undergoing dedifferentiation with time.
AcknowlegeueumtS7
R Rajakariar undertook these studies while an Intercalated BSc
student, with support from the Jean Shanks Foundation. We are
grateful to Mrs S Dearing for technical support and Mrs Diana
Peters for typing the manuscript.
References
ALLRED DC. CLARK GM. MOLINA R. TANDON AK. SCHNITT SJ.
GILCHRIST KW. OSBORNE CK. TORMEY DC AND MCGUIRE
WL. (1992). Overexpression of HER-2/neu and its relationship
with other prognostic factors change during the progression of
in-situ to invasive breast cancer. Hwn. Patho., 23, 974-979.
ANDERSON TJ. LAMB J. ALEXANDER FE. LUTZ W, CHETTY U.
FORREST APM. KIRKPATRICK A, MUIR B. ROBERTS MM AND
HUGGINS A. (1986). Comparative pathology of prevalent and
incident cancers detected by breast screening. Lancet, i, 519-523.
ANDERSON TJ. LAMB J. DONNAN P. ALEXANDER FE, HUGGINS A.
MUIR BB. KIRKPATRICK AE. CHETTY U, HEPBURN W. SMITH
A. PRESCOTT RJ AND FORREST P. (1991). Comparative
pathology of breast cancer in a radnomised tnral of screening. Br.
J. Cancer, 64, 108-113.
BARNES DM. DUBLIN EA, FISHER CJ. LEVISON DA AND MILLIS
RR. (1993). Immunohistochemical detection of p53 protein in
mammary carcinoma: an important new independent indication
of prognosis? Hum. Pathol.. 24, 469-476.
BRUUN RASMUSSEN B. ROSE C. THORPE SM. HOU-JENSEN K.
DAEHNFELDT JL AND PALSHOF T. (1981). Histopathological
characteristics and oestrogen receptor content in primary breast
carcinoma. Virchows Arch. Pathol. Anat., 39, 347-351.
CATTORETTI G. BECKER MHG. KEY G. DUCHROW M. SCHLUTER
C. GALLE J AND GERDES J. (1992). Monoclonal antibodies
againt recombinant parts of the Ki-67 antigen [MIB-l and MIB-
3] detect proliferating cells in microwave processed formalin-fixed
paraffin sections. J. Pathol.. 168, 357-363.
CHAMBERLAIN Ji COLEMAN D. ELLMAN R AND MOSS SM. (1988).
First results on mortality reduction in the UK trial of early
detection of breast cancer. Lancet. n, 411-416.
COWAN WK, ANGUS B. HENRY J. CORBETT IP. REID WA AND
HORNE CHW. (1991). Immunohistochemical and other features of
breast carcinomas presenting clinically with those detected by
cancer screening. Br. J. Cancer, 64, 780-784.
ELLIS IO, GALEA M, BROUGHTON N. LOCKER A. BLAMEY RW
AND ELSTON CW. (1992). Pathological prognostic factors in
breast cancer. II. Histological type. Relationship with survival in
a large study with long-term follow-up. Histopathology, 20,
479-489.
ELLIS IO, GALEA M. LOCKER A, ROEBUCK El, ELSTON CW,
BLAMEY RW AND WILSON ARM. (1993). Early experience in
breast cancer screening: emphasis on development of protocols
for triple assessment. Breast, 2, 148-153.
ELSTON CW AND ELLIS 10. (1991). Pathological prognostic factors
in breast cancer. I. The value of histological grade in breast
cancer: experience from a large study with long term follow up.
Histopathology, 19, 403-40.
FOEKENS JA, RIO MC, SEGUIN P, VAN PUTTEN WLJ, FAUQUE J,
NAP M, KLIUN JGM & CHAMBON P. (1990). Prediction of relapse
and survival in breast cancer patients by pS2 protein status.
Cancer Res., 50, 3832-3837.
GERDES J, LEMKE H, BAISCH H, WACHER H-H, SCHWAB V AND
S`TEIN H. (1984). Cell cycle analysis of a cell proliferation-
associated human nuclear antigen defined by the monoclonal
antibody Ki-67. J. Immunol., 133, 1710-1715.
HENRY JA, MCCARTHY AL, ANGUS B, WESTLEY BR, MAY FEB,
NICHOLSON S, CAIRNS J, HARRIS AL AND HORNE CHW_
(1990). Prognostic significance of the oestrogen regulated protein,
cathepsin D, in breast cancer. Cancer, 65, 265-277.
HENRY JA, PIGGOIT NH, MALLICK UC. NICHOLSON S, FARNDON
JR, WESTLEY BR AND MAY FEB. (1991). pNR-2/pS2 immunohis-
tochemical staining in breast cancer. correlation with prognostic
factors and endocrine response. Br. J. Cancer, 62, 615-622.
KLEMI PJ, JOENSUU H, TOIKKANEN S, TUOMINEN J, RASANEN 0,
TYRKKO J AND PARVINEN I. (1992). Aggressiveness of breast
cancer found with and without screening. Br. Med. J., 304,
467-469.Naure d imnpapmle bk- cance
R Ralakarnar and RA Walker
154
LINELL F. LIUNBERG 0 AND ANDERSSON I. (1980). Breast car-
cinoma aspects of early stages, progression and related problems.
Acta Pathol. Microbiol. Scand., Suppl. 272, 63-101.
MCCLELLAND RA, WILSON D. LEAKE R. FINLAY P AND NICHOL-
SON RI. (1991). A multicentre study into the reliability of steroid
receptor immunocytochemical assay quantification. Eur. J.
Cancer, 27, 711-715.
MCKINNEY CD. FRIERSON HF. FECHNER RE. WILHELM MC AND
EDGE SB. (1992). Pathologic findings in nonpalpable invasive
breast cancer. Am J. Surg. Pathol., 16, 33-36.
POLLER DN. HUTCHINGS CE. GALEA M, BELL JA. NICHOLSON RA.
ELSTON CW. BLAMEY RW AND ELLIS 10. (1992). p53 protein
expression in human breast carcinomas: relationship to expres-
sion of epidermal growth factor receptor c-erbB-2 protein overex-
pression and oestrogen receptor. Br. J. Cancer, 66, 583-588.
PUJOL P. MAUDELONDE T. DAURES J-P. ROUANET P, BROUILLET
J-P. PUJOL H AND ROCHEFORT H. (1993). A prospective study
of the prognostic value of cathepsin D levels in breast cancer
cytosol. Cancer, 71, 2006-2012.
ROBERTS MM. ALEXANDER FE. ANDERSON TJ. CHETTY V. DON-
NAN PT AND FORREST APM. (1990). Edinburgh trial of screen-
ing for breast cancer: mortality at seven years. Lancet, 335,
241-246.
ROYAL COLLEGE OF PATHOLOGISTS WORKING GROUP. (1990).
NHS Breast Screening Programme: Pathology Reporting in Breast
Cancer Screening. London: Royal College of Pathologists.
SHAPIRO S. VENET W. STRAX P. VENET L AND ROESER R. (1985).
Selection, follow-up and analysis in the health insurance plan
study: a randomized trial with breast cancer screening. Natil
Cancer Inst. Monogr., 67, 65-74.
SOOMRO S. SHOOSHA S AND SINNET HD. (1992). Oestrogen and
progesterone receptors in screen-detected breast carcinoma: an
immunohistological study using paraffin sections. Histopathologv,
21, 543-547.
SPYRATOS F. MAUDELONDE T. BROUILLET J. BRUNET M.
DEFRENNE A. ADRIEN C. HACENE K. DESPLACES A. ROUESSE
I AND ROCHEFORT H. (1989). Cathepsin D: an independent
prognostic factor for metastasis of breast cancer. Lancet. i,
1115-1118.
STAL 0. BRISFORS A. CARSTENSEN J. FERRAUD L. HATSCHEK T.
NORDENSKJOLD AND THE SOUTH-EAST SWEDEN BREAST
CANCER GROUP. (1992). Relationships of DNA ploidy, S-phase
fraction and hormone receptor status to tumour stage in breast
cancer detected by population screening. Int. J. Cancer. 51,
28-33.
TABAR L. FAGERBERG CJG. GAD A. BALDETORP L. HOLMBERG
LH AND GRONTOFT 0. (1985). Reduction in mortality from
breast cancer after mass screening with mammography. Lancet, i,
829-832.
TABAR L. FAGERBERG G. DAY NE. DUFFY SW AND KITCHIN RM.
(1992). Breast cancer treatment and natural history: new insights
from results of screening. Lancet, 339, 412-415.
TANDON AK. CLARK GM. CHAMNESS GC. CHIRGWIN JM AND
MCGUIRE WL_ (1990). Cathepsin D and prognosis in breast
cancer. N. Engl. J. Med., 322, 297-302.
THOR AD. KOERNER FC. EDGERTON SM. WOOD WC. STRACHER
MA AND SCHWARTZ LH. (1992). pS2 expression in pnrmary
breast carcinomas: relationship to clinical and histological
features and survival. Breast Cancer Res. Treat., 21, 111-119.
VERBEEK ALM, HOLLAND R. STURMANS F. HENDRICKS JHCL.
MRAVUNAC M AND DAY NE. (1984). Reduction of breast cancer
mortality through mass screening with modern mammography.
First results of the Nijmegen project, 1975-1981. Lancet, ii,
1222-1224.
WALKER RA, GULLICK WJ AND VARLEY J. (1989). An evaluation
of immunoreactivity for c-erbB-2 protein as a marker of short-
term prognosis in breast cancer. Br. J. Cancer. 60, 426-429.
WALKER RA. DEARING SJ. LANE DP AND VARLEY IM. (1991).
Expression of p53 protein in infiltrating and in-situ breast car-
cinoma. J. Pathol., 165, 203-211.
WALKER RA. DENLEY H AND DOOKERAN KA. (1994). Cathepsin
D in breast carcinomas-the role of the stromal cell component.
Oncology Rep.. 1, 227-231.